Effects of Ghrelin Administration After Total Gastrectomy: A Prospective, Randomized, Placebo-Controlled Phase II Study

Shinichi Adachi, Shuji Takiguchi, Kazuyuki Okada, Kazuyoshi Yamamoto, Makoto Yamasaki, Hiroshi Miyata, Kiyokazu Nakajima, Yoshiyuki Fujiwara, Hiroshi Hosoda, Kenji Kangawa, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Background & Aims: Body weight (BW) loss and reduction of blood ghrelin level are commonly observed after total gastrectomy (TG). A prospective study was designed to elucidate whether exogenous ghrelin administration prevents postoperative BW loss by improving appetite and oral food intake in patients with gastric cancer after undergoing TG. Methods: In this randomized phase II study, 21 patients undergoing TG were assigned to a ghrelin (11 patients) or placebo group (10 patients). They received intravenous infusion of synthetic human ghrelin (3 μg/kg) or saline twice daily for 10 days after starting oral food intake following surgery. Changes in BW, appetite visual analog scale score, food intake calories, body composition, basal metabolic rate, and various blood test results were evaluated. Results: Excluding one patient who developed profound diaphoresis during ghrelin infusion, 20 patients completed the study. Food intake and appetite were significantly higher with ghrelin compared with placebo (average, 13.8 vs 10.4 kcal/kg/day [P = .030] and 5.7 vs 3.9 cm [P = .032], respectively). BW loss was significantly lower in the ghrelin than in the placebo group (-1.4% vs -3.7%; P = .044). Fat mass, lean body mass, and basal metabolic rate decreased significantly in the placebo group; however, the reductions in lean body mass and basal metabolic rate were not significant in the ghrelin group, although that of fat mass was significant. Conclusions: Short-term administration of synthetic ghrelin was safe and successfully lessened postoperative BW loss and improved appetite and food intake after TG.

Original languageEnglish
Pages (from-to)1312-1320
Number of pages9
JournalGastroenterology
Volume138
Issue number4
DOIs
Publication statusPublished - Jan 1 2010
Externally publishedYes

Fingerprint

Ghrelin
Gastrectomy
Placebos
Weight Loss
Appetite
Basal Metabolism
Eating
Body Weight
Fats
Body Weight Changes
Hematologic Tests
Body Composition
Visual Analog Scale
Intravenous Infusions
Stomach Neoplasms
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Adachi, S., Takiguchi, S., Okada, K., Yamamoto, K., Yamasaki, M., Miyata, H., ... Doki, Y. (2010). Effects of Ghrelin Administration After Total Gastrectomy: A Prospective, Randomized, Placebo-Controlled Phase II Study. Gastroenterology, 138(4), 1312-1320. https://doi.org/10.1053/j.gastro.2009.12.058

Effects of Ghrelin Administration After Total Gastrectomy : A Prospective, Randomized, Placebo-Controlled Phase II Study. / Adachi, Shinichi; Takiguchi, Shuji; Okada, Kazuyuki; Yamamoto, Kazuyoshi; Yamasaki, Makoto; Miyata, Hiroshi; Nakajima, Kiyokazu; Fujiwara, Yoshiyuki; Hosoda, Hiroshi; Kangawa, Kenji; Mori, Masaki; Doki, Yuichiro.

In: Gastroenterology, Vol. 138, No. 4, 01.01.2010, p. 1312-1320.

Research output: Contribution to journalArticle

Adachi, S, Takiguchi, S, Okada, K, Yamamoto, K, Yamasaki, M, Miyata, H, Nakajima, K, Fujiwara, Y, Hosoda, H, Kangawa, K, Mori, M & Doki, Y 2010, 'Effects of Ghrelin Administration After Total Gastrectomy: A Prospective, Randomized, Placebo-Controlled Phase II Study', Gastroenterology, vol. 138, no. 4, pp. 1312-1320. https://doi.org/10.1053/j.gastro.2009.12.058
Adachi, Shinichi ; Takiguchi, Shuji ; Okada, Kazuyuki ; Yamamoto, Kazuyoshi ; Yamasaki, Makoto ; Miyata, Hiroshi ; Nakajima, Kiyokazu ; Fujiwara, Yoshiyuki ; Hosoda, Hiroshi ; Kangawa, Kenji ; Mori, Masaki ; Doki, Yuichiro. / Effects of Ghrelin Administration After Total Gastrectomy : A Prospective, Randomized, Placebo-Controlled Phase II Study. In: Gastroenterology. 2010 ; Vol. 138, No. 4. pp. 1312-1320.
@article{ab04f35a6aff417fa93ac5516d601c54,
title = "Effects of Ghrelin Administration After Total Gastrectomy: A Prospective, Randomized, Placebo-Controlled Phase II Study",
abstract = "Background & Aims: Body weight (BW) loss and reduction of blood ghrelin level are commonly observed after total gastrectomy (TG). A prospective study was designed to elucidate whether exogenous ghrelin administration prevents postoperative BW loss by improving appetite and oral food intake in patients with gastric cancer after undergoing TG. Methods: In this randomized phase II study, 21 patients undergoing TG were assigned to a ghrelin (11 patients) or placebo group (10 patients). They received intravenous infusion of synthetic human ghrelin (3 μg/kg) or saline twice daily for 10 days after starting oral food intake following surgery. Changes in BW, appetite visual analog scale score, food intake calories, body composition, basal metabolic rate, and various blood test results were evaluated. Results: Excluding one patient who developed profound diaphoresis during ghrelin infusion, 20 patients completed the study. Food intake and appetite were significantly higher with ghrelin compared with placebo (average, 13.8 vs 10.4 kcal/kg/day [P = .030] and 5.7 vs 3.9 cm [P = .032], respectively). BW loss was significantly lower in the ghrelin than in the placebo group (-1.4{\%} vs -3.7{\%}; P = .044). Fat mass, lean body mass, and basal metabolic rate decreased significantly in the placebo group; however, the reductions in lean body mass and basal metabolic rate were not significant in the ghrelin group, although that of fat mass was significant. Conclusions: Short-term administration of synthetic ghrelin was safe and successfully lessened postoperative BW loss and improved appetite and food intake after TG.",
author = "Shinichi Adachi and Shuji Takiguchi and Kazuyuki Okada and Kazuyoshi Yamamoto and Makoto Yamasaki and Hiroshi Miyata and Kiyokazu Nakajima and Yoshiyuki Fujiwara and Hiroshi Hosoda and Kenji Kangawa and Masaki Mori and Yuichiro Doki",
year = "2010",
month = "1",
day = "1",
doi = "10.1053/j.gastro.2009.12.058",
language = "English",
volume = "138",
pages = "1312--1320",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Effects of Ghrelin Administration After Total Gastrectomy

T2 - A Prospective, Randomized, Placebo-Controlled Phase II Study

AU - Adachi, Shinichi

AU - Takiguchi, Shuji

AU - Okada, Kazuyuki

AU - Yamamoto, Kazuyoshi

AU - Yamasaki, Makoto

AU - Miyata, Hiroshi

AU - Nakajima, Kiyokazu

AU - Fujiwara, Yoshiyuki

AU - Hosoda, Hiroshi

AU - Kangawa, Kenji

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background & Aims: Body weight (BW) loss and reduction of blood ghrelin level are commonly observed after total gastrectomy (TG). A prospective study was designed to elucidate whether exogenous ghrelin administration prevents postoperative BW loss by improving appetite and oral food intake in patients with gastric cancer after undergoing TG. Methods: In this randomized phase II study, 21 patients undergoing TG were assigned to a ghrelin (11 patients) or placebo group (10 patients). They received intravenous infusion of synthetic human ghrelin (3 μg/kg) or saline twice daily for 10 days after starting oral food intake following surgery. Changes in BW, appetite visual analog scale score, food intake calories, body composition, basal metabolic rate, and various blood test results were evaluated. Results: Excluding one patient who developed profound diaphoresis during ghrelin infusion, 20 patients completed the study. Food intake and appetite were significantly higher with ghrelin compared with placebo (average, 13.8 vs 10.4 kcal/kg/day [P = .030] and 5.7 vs 3.9 cm [P = .032], respectively). BW loss was significantly lower in the ghrelin than in the placebo group (-1.4% vs -3.7%; P = .044). Fat mass, lean body mass, and basal metabolic rate decreased significantly in the placebo group; however, the reductions in lean body mass and basal metabolic rate were not significant in the ghrelin group, although that of fat mass was significant. Conclusions: Short-term administration of synthetic ghrelin was safe and successfully lessened postoperative BW loss and improved appetite and food intake after TG.

AB - Background & Aims: Body weight (BW) loss and reduction of blood ghrelin level are commonly observed after total gastrectomy (TG). A prospective study was designed to elucidate whether exogenous ghrelin administration prevents postoperative BW loss by improving appetite and oral food intake in patients with gastric cancer after undergoing TG. Methods: In this randomized phase II study, 21 patients undergoing TG were assigned to a ghrelin (11 patients) or placebo group (10 patients). They received intravenous infusion of synthetic human ghrelin (3 μg/kg) or saline twice daily for 10 days after starting oral food intake following surgery. Changes in BW, appetite visual analog scale score, food intake calories, body composition, basal metabolic rate, and various blood test results were evaluated. Results: Excluding one patient who developed profound diaphoresis during ghrelin infusion, 20 patients completed the study. Food intake and appetite were significantly higher with ghrelin compared with placebo (average, 13.8 vs 10.4 kcal/kg/day [P = .030] and 5.7 vs 3.9 cm [P = .032], respectively). BW loss was significantly lower in the ghrelin than in the placebo group (-1.4% vs -3.7%; P = .044). Fat mass, lean body mass, and basal metabolic rate decreased significantly in the placebo group; however, the reductions in lean body mass and basal metabolic rate were not significant in the ghrelin group, although that of fat mass was significant. Conclusions: Short-term administration of synthetic ghrelin was safe and successfully lessened postoperative BW loss and improved appetite and food intake after TG.

UR - http://www.scopus.com/inward/record.url?scp=77949850987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949850987&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2009.12.058

DO - 10.1053/j.gastro.2009.12.058

M3 - Article

C2 - 20060830

AN - SCOPUS:77949850987

VL - 138

SP - 1312

EP - 1320

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 4

ER -